Asthma alternative therapy hearing
This article was originally published in The Tan Sheet
Executive Summary
House Government Reform Committee hearing tentatively scheduled for July 20 to discuss complementary and alternative therapies for asthma. The meeting follows two previous hearings convened this spring by committee Chair Dan Burton (R-Ind.) that focused on FDA's collection of dietary supplement adverse events and the proposed redefinition of "disease," respectively (1"The Tan Sheet" May 31, p. 3, and 2March 29, p. 3). Confirmation of the July 20 hearing date awaits commitment from a celebrity witness
You may also be interested in...
FDA Supplement AE Monitoring System Has "Six Problem Areas" - Burton
"Six problem areas" exist in the FDA Center for Food Safety & Applied Nutrition adverse event monitoring system for dietary supplements that need to be resolved, House Government Reform Committee Chairman Dan Burton (R-Ind.) declared at a May 27 hearing.
"Disease" Definition Is Key Issue In Structure/Function Claims Rule - Henney
The appropriateness of the new definition of "disease" included in FDA's April 1998 proposed rule on structure/function claims is a key issue emerging from the more than 100,000 comments received on the proposal, FDA Commissioner Jane Henney, MD, noted at a House Government Reform Committee hearing March 25. The hearing was called to review FDA's implementation of the Dietary Supplement Health & Education Act, and, in particular, the structure/function claims proposal.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC